Leading doctors, advocacy groups, medical organizations and U.S. TB programs call upon Sanofi to lower the price of rifapentine to ensure its accessibility and continue and expand its investments in the development of the drug for active TB.
"The millions of people worldwide with TB (including nearly 10,000 people in the U.S. alone, and their hundreds of thousands of infected contacts) need better treatment options urgently. And care providers, TB programs and taxpayers urgently need these to be affordable, now. Sanofi, we ask you to take a stand and demonstrate your commitment to rifapentine development and access by:
1. Lowering the price of rifapentine to $35 per box of 32 tablets of 150 mg; and
2. Pledging $2 million to the TBTC for the continued development of rifapentine."